EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A Comparison of Faster Insulin Aspart with Standard Insulin Aspart Using Hybrid Automated Insulin Delivery System in Active Children and Adolescents with Type 1 Diabetes: A Randomized Double-Blind Crossover Trial

Klemen Dovc iD, Simon Bergford, Elke Fröhlich-Reiterer, Dessi P Zaharieva iD, Nejka Potocnik, Alexander Müller, Ziva Lenarcic, Peter Calhoun iD, Maria Fritsch, Harald Sourij, Natasa Bratina, Craig Kollman und 1 weitere

Diabetes Technology & Therapeutics · 2023-09 · 25 (9) · 612-621

DOI: 10.1089/dia.2023.0178 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 22.08.2023. Verfasst von Klemen Dovc und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Insulin Aspart, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the use of faster acting (FIA) and standard insulin aspart (SIA) with hybrid automated insulin delivery (AID) in active youth with type 1 diabetes. Research Design and Methods: In this double-blind multinational randomized crossover trial, 30 children and adolescents with type 1 diabetes (16 females; aged 15.0 ± 1.7 years; baseline HbA1c 7.5% ± 0.9% [58 ± 9.8 mmol/mol]) underwent two unrestricted 4-week periods using hybrid AID with either FIA or SIA in random order. During both interventions, participants were using the hybrid AID (investigational version of MiniMed™ 780G; Medtronic). Participants were encouraged to exercise as frequently as possible, capturing physical activity with an activity monitor. The primary outcome was the percentage of sensor glucose time above range (180 mg/dL [10.0 mmol/L]) measured by continuous glucose monitoring.

Results

In an intention-to-treat analysis, mean time above range was 31% ± 15% at baseline, 19% ± 6% during FIA use, and 20% ± 6% during SIA use with no difference between treatments: mean difference = −0.9%; 95% CI: −2.4% to 0.6%; P = 0.23. Similarly, there was no difference in mean time in range (TIR) (78% and 77%) or median time below range (2.5% and 2.8%). Glycemic outcomes during exercise or postprandial periods were comparable for the two treatment arms. No severe hypoglycemia or diabetic ketoacidosis events occurred.

Conclusions

FIA was not superior to SIA with hybrid AID system use in physically active children and adolescents with type 1 diabetes. Nonetheless, both insulin formulations enabled high overall TIR and low time above and below ranges, even during and after documented exercise. Trial Registration Clinicaltrials.gov: NCT04853030.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin AspartDiabetes Mellitus, Type 1FemaleAdolescentHumansChildInsulinHypoglycemic AgentsCross-Over StudiesBlood Glucose Self-MonitoringBlood GlucoseInsulin, Regular, HumanDouble-Blind Method

Stichwörter der Autor:innen

AdolescentsAutomated insulin deliveryChildrenExerciseFaster acting insulinType 1 diabetes

Substanzen

Insulin AspartInsulinHypoglycemic AgentsBlood GlucoseInsulin, Regular, Human

Autor:innen und Institutionen

  • Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, Ljubljana, Slovenia.
  • Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Jaeb Center for Health Research Foundation, Inc., Tampa, Florida, USA.
  • Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.
  • Division of Endocrinology, Department of Pediatrics, Stanford University, Stanford, California, USA.
  • Faculty of Medicine, Institute of Physiology, University of Ljubljana, Ljubljana, Slovenia.

ORCID-Profile: Klemen Dovc, Dessi P Zaharieva, Peter Calhoun, Tadej Battelino

Zitieren

APA

Dovc, K., Bergford, S., Fröhlich-Reiterer, E., Zaharieva, D. P., Potocnik, N., Müller, A., Lenarcic, Z., Calhoun, P., Fritsch, M., Sourij, H., Bratina, N., Kollman, C., & Battelino, T. (2023). A Comparison of Faster Insulin Aspart with Standard Insulin Aspart Using Hybrid Automated Insulin Delivery System in Active Children and Adolescents with Type 1 Diabetes: A Randomized Double-Blind Crossover Trial. Diabetes Technology & Therapeutics, 25(9), 612-621. https://doi.org/10.1089/dia.2023.0178

Vancouver

Dovc K, Bergford S, Fröhlich-Reiterer E, Zaharieva DP, Potocnik N, Müller A, et al. A Comparison of Faster Insulin Aspart with Standard Insulin Aspart Using Hybrid Automated Insulin Delivery System in Active Children and Adolescents with Type 1 Diabetes: A Randomized Double-Blind Crossover Trial. Diabetes Technology & Therapeutics. 2023;25(9):612-621. doi:10.1089/dia.2023.0178

BibTeX
@article{Dovc2023,
  author = {Dovc, Klemen and Bergford, Simon and Fröhlich-Reiterer, Elke and Zaharieva, Dessi P and Potocnik, Nejka and Müller, Alexander and Lenarcic, Ziva and Calhoun, Peter and Fritsch, Maria and Sourij, Harald and Bratina, Natasa and Kollman, Craig and Battelino, Tadej},
  title = {A Comparison of Faster Insulin Aspart with Standard Insulin Aspart Using Hybrid Automated Insulin Delivery System in Active Children and Adolescents with Type 1 Diabetes: A Randomized Double-Blind Crossover Trial},
  journal = {Diabetes Technology & Therapeutics},
  year = {2023},
  volume = {25},
  number = {9},
  pages = {612--621},
  doi = {10.1089/dia.2023.0178}
}
Kostenlos starten →